Bezlotoxumab (Zinplava) for Clostridium Difficile Infection: The First Monoclonal Antibody Approved to Prevent the Recurrence of a Bacterial Infection.

Link to article at PubMed

Related Articles

Bezlotoxumab (Zinplava) for Clostridium Difficile Infection: The First Monoclonal Antibody Approved to Prevent the Recurrence of a Bacterial Infection.

P T. 2017 Dec;42(12):735-738

Authors: Lee Y, Lim WI, Bloom CI, Moore S, Chung E, Marzella N

Abstract
Bezlotoxumab (Zinplava) to prevent the recurrence of Clostridium difficile infection.

PMID: 29234211 [PubMed]

Leave a Reply

Your email address will not be published.